Comparison Of 150 Iu And 225 Iu Of Follitropin-Beta In A Fixed-Dose Regimen For Ovarian Stimulation Using A Depot Formulation Of Gnrh Agonist: A Prospective Randomized Clinical Trial.

This prospective and randomized study included 76 normoovulatory women undergoing assisted reproductive technology cycles using the long protocol of GnRH agonist who received either 150 IU (group A, n=40) or 200 IU (group B, n=36) of recombinant FSH (follitropin-beta) per day in a fixed-dose regimen. Four outcome measures including percentage of mature oocytes collected, fertilization rate, pregnancy rate and total dose of follitropin-beta administered were compared between the groups. Percentage of mature oocytes retrieved (91% in group A versus 87.1% in group B), fertilization rate (69% in group A versus 74% in group B) and pregnancy rate per transfer (25.0% in group A versus 26.6% in group B), were not statistically different in both groups. The mean dose of recombinant FSH administered was lower in group A (1,620 +/- 215 IU in group A versus 2,078 +/- 275 in group B). It is concluded that the dose of 150 IU of follitropin-beta is more cost-effective and may be the dose of choice to be employed for ovarian stimulation with a fixed-dose regimen in normo-ovulatory women with age less than 35 years.